From tissue repair to metabolism to how cells age, the word “peptide” covers far more science than most people realize. Here’s how to tell them apart.
First, a number that reframes the whole conversation
Peptides are short chains of amino acids, the same building blocks that make up proteins. Think of them as proteins’ shorter, chattier cousins. Your body makes many of them on its own. Others are manufactured or modified to imitate, extend or study a particular biological signal.
None of this is new. Insulin entered medicine more than a hundred years ago, and peptide-based treatments now exist for conditions involving hormones, metabolism, bone health and more.
THE NUMBER TO REMEMBER: ROUGHLY 100
By one 2024 count, about 100 peptide therapeutics have received FDA authorization over the history of peptide drug development.
Before anyone gets excited: that does not mean 100 peptides are approved for longevity, recovery or “wellness.” Not even close. It means peptides are an established branch of medicine with a long track record, plus an expanding frontier of newer, much less settled research.
That’s the distinction to keep in mind for the rest of this article: peptides as a scientific class versus the evidence for any one peptide. Some have decades of clinical use behind them. Some are in early human studies. Some have mostly been studied in petri dishes and lab animals. They’re in the same family, but their research histories are very different.
Tissue repair: the body’s construction crew
That’s the distinction to keep in mind for the rest of this article: peptides as a scientific class versus the evidence for any one peptide. Some have decades of clinical use behind them. Some are in early human studies. Some have mostly been studied in petri dishes and lab animals. They’re in the same family, but their research histories are very different.
Think about what happens when you tweak a tendon (say, reaching for something on the top shelf that you absolutely could have asked someone else to grab).
Your body doesn’t show up with duct tape and good intentions. It runs a coordinated project: inflammation, new blood-vessel activity, cells migrating to the site, collagen being laid down and then reorganized. Different signals manage different stages of the job.
Researchers want to know whether certain peptides can influence those signals.
BPC-157 is the name you’ve probably heard most. Its research has looked at tissue protection and repair in experimental models involving the gut, tendons and other structures, with mechanisms involving blood vessels and inflammatory signaling. One “I didn’t know that”: a 2025 systematic review screened hundreds of BPC-157 papers for orthopedic relevance and found that nearly all of the evidence comes from animal studies. Published human data amounts to a handful of very small, uncontrolled reports.
TB-500 is usually linked to research on thymosin beta-4, a peptide your body produces naturally. Thymosin beta-4 helps regulate actin, the scaffolding that lets cells move and reorganize, and moving cells is a big part of repairing tissue. One caveat: TB-500 and full-length thymosin beta-4 aren’t necessarily the same molecule, so findings about one can’t simply be credited to the other.
GHK-Cu, the copper-binding peptide you’ve likely seen on a skincare label, has research interest in collagen-related processes and tissue remodeling.
Notice that these three aren’t all doing the same thing. Researchers are looking at different points in the repair process. That’s a much better story than lumping them together as “recovery peptides.”
Human research on musculoskeletal healing is still developing, but the laboratory and animal findings have given researchers some intriguing directions to pursue. What makes this category fascinating is the possibility of understanding tissue repair at a much more precise biological level. Instead of treating recovery as one process, scientists are investigating the individual signals that help coordinate it. That’s a compelling reason to keep studying these peptides, even while the human evidence catches up.
Metabolism: your organs have a group chat
If tissue repair is a construction project, metabolism is a group chat.
Your gut, pancreas, brain, liver, muscles and fat tissue are constantly messaging each other about energy: what came in, what’s stored, what’s needed. Many of those messages are carried by peptide hormones.
The most famous example right now is the GLP-1 family, including semaglutide and tirzepatide, which acts on both GIP and GLP-1 receptors. These drugs didn’t come from someone trying to build a better appetite suppressant. They came from decades of research into hormones your gut was already using to tell your brain “okay, we’re good,” long before anyone had heard the word Ozempic.
The science also goes beyond hunger. GLP-1 signaling helps release insulin in a glucose-dependent way, meaning it responds when blood sugar rises, and related pathways affect other parts of metabolic regulation. That research has produced treatments with substantial evidence for specific conditions.
Now consider a very different molecule: MOTS-c, a peptide encoded by mitochondria.
You’ve probably heard mitochondria called “the powerhouse of the cell,” which is true but undersells them. They also sense when a cell’s energy situation changes and help coordinate the response. That makes their signaling especially interesting to aging researchers.
MOTS-c has shown intriguing metabolic effects in experimental systems, but human research is early. It does not have anything close to the clinical record of GLP-1 medicines.
That’s the takeaway: both belong in a conversation about metabolic peptides, but they sit in very different places on the evidence map. One area has produced widely studied prescription drugs. The other is helping scientists ask new questions. What they share isn’t weight loss. It’s the body communicating about energy.
Brain signaling: messengers with a lot to say
Your brain runs on chemical messengers that help manage everything from focus and mood to sleep and how you handle stress. Some of those messengers are peptides.
So studying peptides for brain function is much less far-fetched than it sounds.
Two names that come up often are Semax and Selank, both with research histories rooted largely in Russia, and each tied to different questions.
Semax has been studied for neurological function, neuroprotection and neurotrophic signaling, the systems that help nerve cells survive and adapt. Selank has drawn interest for its possible relationship to anxiety-related processes and stress responses.
What makes them interesting is that they aren’t being studied as simple stimulants or sedatives. The research asks whether specific peptide structures can influence more complex signaling systems. Could a peptide shift how the nervous system responds to stress? Could it affect learning, attention or neurological recovery? These are legitimate scientific questions.
But decades of research interest isn’t the same as decades of large, independently replicated trials. For Semax and Selank, internationally accessible human evidence is still thin compared with established neurological and psychiatric treatments. That doesn’t erase the history. It tells us which questions still need better answers.
Growth hormone signaling: different doors into the same house
Here’s a distinction that gets lost almost every time: some peptides don’t replace a hormone. They nudge the system that controls it.
Growth hormone is managed by a network that includes the brain, the pituitary gland, the liver and other tissues. That regulation changes as we age, and growth hormone affects growth, metabolism and tissue health.
Several peptides interact with different parts of that network:
- Sermorelin mimics growth hormone-releasing hormone. Think of it as knocking on the pituitary’s front door.
- Ipamorelin works through the ghrelin receptor, the same receptor as your hunger hormone. That’s more like coming in through the side door.
Same house, different doors. They are not interchangeable.
Then there’s tesamorelin, a modified growth hormone-releasing factor analogue with a real prescription use. In the U.S. it’s approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is for that specific condition only. It isn’t for general weight loss or healthy aging.
Why go into this much detail? Because growth hormone shows how one biological pathway can include several distinct compounds, each with its own mechanism, clinical history and regulatory status. Also, more of a hormone isn’t automatically better. Hormone systems are connected, and changing one signal can affect others, including blood sugar and tissue growth.
The real scientific question isn’t “is more growth hormone good?” It’s whether carefully targeting a pathway produces a useful, measurable result in the right setting.
Cellular aging: where things get really interesting
For a long time, aging was described by what we could see declining: muscle, skin, energy, memory, how long it takes to bounce back from a bad night’s sleep.
Modern aging research asks a different question: what’s changing inside our cells that drives all of that?
Scientists study mitochondrial function, cellular stress responses, DNA maintenance, inflammation and the regulation of gene activity. Peptides come into the picture because some of them take part in those signaling systems.
Epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide studied in connection with telomeres. Telomeres are the protective caps on the ends of chromosomes, a bit like the plastic tips on shoelaces, and they’ve become a major topic in aging research. Experimental studies have explored whether epitalon affects telomerase activity and related processes.
That’s fascinating biology. But a lab marker moving in the right direction isn’t the same as people living longer or staying healthier. Your car’s check-engine light going off doesn’t prove the engine got fixed. Reliable human evidence showing those outcomes for epitalon doesn’t exist yet.
The same applies to other investigational peptides tied to mitochondrial function or cellular resilience. Researchers often find an effect on a molecular pathway long before they know whether changing that pathway helps people.
That isn’t a failure. It’s how research works.
The most exciting possibility probably isn’t one peptide becoming a universal anti-aging fix. It’s that understanding these signaling systems could eventually give us more precise ways to study, and maybe address, specific parts of age-related biology.
THE SEPTEMBER TAKE
Peptides get much more interesting when you stop treating them as one product category and start seeing them as different biological messages.
Some messages manage metabolism. Some adjust hormone signaling. Others are being studied for tissue repair, brain function or cellular aging.
The exciting part isn’t that every peptide does everything. It’s that different peptides may help researchers solve very different problems.
Understand the message, and you’re on your way to understanding the science.
One last thing: how a peptide gets in matters
There’s a reason peptide research includes injections, pills, nasal sprays and creams. And the delivery method isn’t just a technical detail. It can fundamentally change what researchers are able to investigate.
Many peptides are broken down during digestion, while others struggle to cross the skin barrier. Injectable delivery offers researchers a way to bypass some of those obstacles, which is one reason injections have played such an important role in peptide medicine and research.
That doesn’t mean every injectable peptide produces a meaningful clinical benefit, or that bypassing digestion establishes its safety. It means delivery is a fascinating part of the science. The same molecule can behave differently depending on how it enters the body, how much reaches circulation and where it ultimately goes.
Delivery changes exposure. It doesn’t replace evidence.
And that’s why delivery research matters so much: understanding how to get a peptide to the right biological target may be just as important as discovering what that peptide can do.
Whenever you hear that a peptide “does” something, ask three questions: Which molecule? Delivered how? And what kind of research backs up that specific claim? Those answers will tell you far more than whether something is labeled a peptide.
Do this week
1. Stop treating “peptides” as one ingredient.
When a peptide name comes up, look at which pathway it’s being studied for instead of assuming it’s in the same bucket as all the others.
2. Separate the mechanism from the outcome.
A compound affecting a cellular pathway is interesting. Proving it improves something that matters in people is a different, much harder achievement.
3. Pay attention to delivery.
Topical, oral, nasal and injectable forms create very different exposures. Research on one route doesn’t automatically apply to another.
4. Know what stage the evidence is at.
Approved prescription peptides, early human studies and lab research all add to the field, but they answer very different questions.
5. Follow the questions, not just the names.
Tissue repair, metabolism, brain signaling and cellular aging are each worth understanding on their own terms.
Next time someone tells you peptides are either miraculous or a total scam, you’ll have a better question ready:
Which peptide are we talking about?
That’s where the real conversation starts.
This article is for educational purposes only and is not medical advice. Discussion of investigational peptides does not establish their safety or effectiveness for human use. Research findings, regulatory status and clinical evidence vary substantially between individual compounds.
Sources & Further Reading
1. Al Musaimi O. Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms. Biomolecules, 2024.
On the history and scope of FDA-approved peptide therapeutics.
2. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology, 2024.
How incretin hormone signaling led to modern metabolic treatments.
3. Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in Aging, 2026.
Reviews nine peptides, including tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax and ipamorelin, and separates established therapies from investigational ones.
4. Vasireddi N, Hahamyan HA, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025.
A systematic review examining the evidence for BPC-157 in orthopedic research, including the substantial gap between animal studies and human clinical evidence.
5. U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) prescribing information. 2025.
Documents tesamorelin’s approved medical indication and limitations of use.
6. Author verification pending. Therapeutic Peptides: Recent Advances in Discovery, Synthesis, and Clinical Translation. 2025.
Discusses peptide development and challenges involving stability, delivery and clinical translation.